Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;7(1 Suppl):S5-S32.
doi: 10.1177/1740774510373497. Epub 2010 Jul 5.

Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC)

Joan E Hilner  1 , Letitia H Perdue, Elizabeth G Sides, June J Pierce, Ana M Wägner, Alan Aldrich, Amanda Loth, Lotte Albret, Lynne E Wagenknecht, Concepcion Nierras, Beena Akolkar; T1DGC
Collaborators, Affiliations

Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC)

Joan E Hilner et al. Clin Trials. 2010.

Abstract

Background and purpose: The Type 1 Diabetes Genetics Consortium (T1DGC) is an international project whose primary aims are to: (a) discover genes that modify type 1 diabetes risk; and (b) expand upon the existing genetic resources for type 1 diabetes research. The initial goal was to collect 2500 affected sibling pair (ASP) families worldwide.

Methods: T1DGC was organized into four regional networks (Asia-Pacific, Europe, North America, and the United Kingdom) and a Coordinating Center. A Steering Committee, with representatives from each network, the Coordinating Center, and the funding organizations, was responsible for T1DGC operations. The Coordinating Center, with regional network representatives, developed study documents and data systems. Each network established laboratories for: DNA extraction and cell line production; human leukocyte antigen genotyping; and autoantibody measurement. Samples were tracked from the point of collection, processed at network laboratories and stored for deposit at National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repositories. Phenotypic data were collected and entered into the study database maintained by the Coordinating Center.

Results: T1DGC achieved its original ASP recruitment goal. In response to research design changes, the T1DGC infrastructure also recruited trios, cases, and controls. Results of genetic analyses have identified many novel regions that affect susceptibility to type 1 diabetes. T1DGC created a resource of data and samples that is accessible to the research community.

Limitations: Participation in T1DGC was declined by some countries due to study requirements for the processing of samples at network laboratories and/or final deposition of samples in NIDDK Central Repositories. Re-contact of participants was not included in informed consent templates, preventing collection of additional samples for functional studies.

Conclusions: T1DGC implemented a distributed, regional network structure to reach ASP recruitment targets. The infrastructure proved robust and flexible enough to accommodate additional recruitment. T1DGC has established significant resources that provide a basis for future discovery in the study of type 1 diabetes genetics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
T1DGC organization chart.
Figure 2
Figure 2
T1DGC data and sample collection flow.
Figure 3
Figure 3
T1DGC blood collection chart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The TEDDY Study Group The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 2007; 8: 286–98 - PubMed
    1. Hagopian WA, Lernmark A, Rewers MJ, et al. TEDDY – The Environmental Determinants of Diabetes in the Young. Ann NY Acad Sci 2006; 1079: 320–26 - PubMed
    1. TRIGR Study Group Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes 2007; 8: 117–37 - PMC - PubMed
    1. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al. The TrialNet natural history study of the development of type 1 diabetes: objective, design and initial results. Pediatr Diabetes 2009; 10: 97–104 - PubMed
    1. Rotrosen D, Matthews JB, Bluestone JA. The immune tolerance network: a new paradigm for developing tolerance-inducing therapies. J Allergy Clin Immunol 2002; 110: 17–23 - PubMed

Publication types